Cite
HARVARD Citation
Buisson, A. et al. (n.d.). P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study. Journal of Crohn's and colitis. pp. i393-i394. [Online].